Tianjin Tianyao Pharmaceuticals Co., Ltd. (600488.SS)

CNY 4.5

(-0.66%)

Market Cap (In CNY)

4.91 Billion

Revenue (In CNY)

3.73 Billion

Net Income (In CNY)

117.05 Million

Avg. Volume

5.24 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.1-5.09
PE
-
EPS
-
Beta Value
0.346
ISIN
CNE000001840
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Shuxiang Li
Employee Count
-
Website
https://www.tjpcty.com
Ipo Date
2001-06-18
Details
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, manufacture, and export of pharmaceutical APIs in Asia. It primarily provides corticosteroid, cardio cerebrovascular, and analgesic APIs and formulations. The company offers bulk drugs, including dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinlone acetonide acetate, prednisone acetate, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone acetonide, clobetasol propionate, betamethasone, methylprednisolone hydrocortisone acetate, methylprednisolone, and triamcinolone. The company is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE : 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.